CAS NO: | 141758-74-9 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-actingglucagon-likepeptide-1 receptor agonist with anIC50of 3.22 nM. | ||||||||||||||||
IC50& Target | IC50: 3.22 nM (glucagon-like peptide-1 receptor)[1] | ||||||||||||||||
体外研究 (In Vitro) | In human umbilical vein endothelial cells, exendin-4 significantly increases NO production, endothelial NO synthase (eNOS) phosphorylation, and GTP cyclohydrolase 1 (GTPCH1) level in a dose-dependent manner[2]. Exendin-4 shows cytotoxic effects to MCF-7 breast cancer cells with IC50of 5 μM at 48 hour[3]. | ||||||||||||||||
体内研究 (In Vivo) | Both low- and high-dose exendin-4 treatment inob/obmice improve serum ALT and reduce serum glucose, and calculated HOMA scores compared with control. Exendin-4-treatedob/obmice sustain a marked reduction in the net weight gain in the final 4 weeks of the study period[4]. Animals treated with exendin-4 have more pancreatic acinar inflammation, more pyknotic nuclei and weigh significantly less than control rats. Exendin-4 treatment is associated with lower leptin levels as well as lower HOMA values in rats[5]. Exenatide causes dose-dependent relaxation of rat thoracic aorta, which is evoked via the GLP-1 receptor and is mediated mainly by H2S but also by NO and CO[6]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 4186.57 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C184H282N50O60S | ||||||||||||||||
CAS 号 | 141758-74-9 | ||||||||||||||||
Sequence | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | ||||||||||||||||
Sequence Shortening | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 | ||||||||||||||||
中文名称 | 艾塞那肽 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Protect from light
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 33.33 mg/mL(7.96 mM;Need ultrasonic) DMSO : ≥ 32 mg/mL(7.64 mM) Ethanol :< 1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|